Summit Therapeutics Inc [NASDAQ: SMMT] stock went on a downward path that fall over -20.47% on Friday, amounting to a one-week price increase of more than 101.04%.
Over the last 12 months, SMMT stock rose by 432.82%. The one-year Summit Therapeutics Inc stock forecast points to a potential upside of 17.24. The average equity rating for SMMT stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $6.10 billion, with 701.66 million shares outstanding and 82.98 million shares in the current float. Compared to the average trading volume of 3.03M shares, SMMT stock reached a trading volume of 34333160 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Summit Therapeutics Inc [SMMT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SMMT shares is $10.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SMMT stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Summit Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 07, 2024. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on March 26, 2024, representing the official price target for Summit Therapeutics Inc stock.
The Average True Range (ATR) for Summit Therapeutics Inc is set at 1.24 The Price to Book ratio for the last quarter was 137.90, with the Price to Cash per share for the same quarter was set at 0.22.
SMMT Stock Performance Analysis:
Summit Therapeutics Inc [SMMT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 101.04. With this latest performance, SMMT shares gained by 84.79% in over the last four-week period, additionally plugging by 345.38% over the last 6 months – not to mention a rise of 432.82% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SMMT stock in for the last two-week period is set at 65.60, with the RSI for the last a single of trading hit 66.71, and the three-weeks RSI is set at 64.49 for Summit Therapeutics Inc [SMMT]. The present Moving Average for the last 50 days of trading for this stock 4.22, while it was recorded at 5.66 for the last single week of trading, and 3.09 for the last 200 days.
Insight into Summit Therapeutics Inc Fundamentals:
Summit Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.97 and a Current Ratio set at 6.97.
Summit Therapeutics Inc [SMMT] Institutonal Ownership Details
The top three institutional holders of SMMT stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in SMMT stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in SMMT stock with ownership which is approximately 5.8386%.
